291 related articles for article (PubMed ID: 19336554)
1. Risk factors for triple-negative breast cancer in women under the age of 45 years.
Dolle JM; Daling JR; White E; Brinton LA; Doody DR; Porter PL; Malone KE
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1157-66. PubMed ID: 19336554
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and breast cancer risk among younger women.
Brinton LA; Daling JR; Liff JM; Schoenberg JB; Malone KE; Stanford JL; Coates RJ; Gammon MD; Hanson L; Hoover RN
J Natl Cancer Inst; 1995 Jun; 87(11):827-35. PubMed ID: 7791232
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer among young U.S. women in relation to oral contraceptive use.
White E; Malone KE; Weiss NS; Daling JR
J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
[TBL] [Abstract][Full Text] [Related]
4. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
[TBL] [Abstract][Full Text] [Related]
5. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
6. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
[TBL] [Abstract][Full Text] [Related]
7. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis.
Fitzpatrick D; Pirie K; Reeves G; Green J; Beral V
PLoS Med; 2023 Mar; 20(3):e1004188. PubMed ID: 36943819
[TBL] [Abstract][Full Text] [Related]
8. Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.
Chollet-Hinton L; Olshan AF; Nichols HB; Anders CK; Lund JL; Allott EH; Bethea TN; Hong CC; Cohen SM; Khoury T; Zirpoli GR; Borges VF; Rosenberg LA; Bandera EV; Ambrosone CB; Palmer JR; Troester MA
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1722-1729. PubMed ID: 28903991
[No Abstract] [Full Text] [Related]
9. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women.
Brinton LA; Gammon MD; Malone KE; Schoenberg JB; Daling JR; Coates RJ
Contraception; 1997 Apr; 55(4):197-203. PubMed ID: 9179450
[TBL] [Abstract][Full Text] [Related]
10. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.
Gaudet MM; Press MF; Haile RW; Lynch CF; Glaser SL; Schildkraut J; Gammon MD; Douglas Thompson W; Bernstein JL
Breast Cancer Res Treat; 2011 Nov; 130(2):587-97. PubMed ID: 21667121
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.
Beaber EF; Malone KE; Tang MT; Barlow WE; Porter PL; Daling JR; Li CI
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):755-64. PubMed ID: 24633144
[TBL] [Abstract][Full Text] [Related]
12. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women.
Islam T; Matsuo K; Ito H; Hosono S; Watanabe M; Iwata H; Tajima K; Tanaka H
Ann Oncol; 2012 Sep; 23(9):2435-2441. PubMed ID: 22328736
[TBL] [Abstract][Full Text] [Related]
13. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
14. The association between oral contraceptive use and lobular and ductal breast cancer in young women.
Nyante SJ; Gammon MD; Malone KE; Daling JR; Brinton LA
Int J Cancer; 2008 Feb; 122(4):936-41. PubMed ID: 17957781
[TBL] [Abstract][Full Text] [Related]
15. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
17. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
18. Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 Apr; 120(7):1026-34. PubMed ID: 24515648
[TBL] [Abstract][Full Text] [Related]
19. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study.
Williams LA; Olshan AF; Tse CK; Bell ME; Troester MA
Cancer Causes Control; 2016 Feb; 27(2):259-69. PubMed ID: 26705260
[TBL] [Abstract][Full Text] [Related]
20. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
